Skip to main content
Premium Trial:

Request an Annual Quote

Analysts Say Market

NEW YORK, March 21 – Traditionally, the market for R&D services and equipment in the life sciences would be considered less susceptible to the vagaries of the business cycle--but try telling that to Michael Hunkapiller, president of Applied Biosystems (ABI).

On Wednesday, Hunkapiller updated the company’s short term business outlook “in light of the recent uncertainty in the economy,” saying that shipments of some of the company’s instruments have been delayed, and that uncertain economic conditions “may influence the near-term buying patterns of other commercial accounts.”

In fact, earlier on Wednesday, Reuters reported that Genaissance had delayed its order of 35 additional sequencers from ABI, and that stock prices for biotech and genomics companies, including ABI and Celera Genomics, had dropped to new 52-week lows.

But analysts said the real reason for the drop in share prices was a lack of investor confidence in general, triggered by the sell-off in technology stocks, and that, if anything, the low share prices could indicate a promising environment for acquiring valuable genomics companies at a reasonable price. 

“A lot of [biotechnology/genomics] companies have made significant technological advances, but the black hole created by technology stocks has taken confidence away from other industries,” said Andrew Scott, an analyst at M. H. Meyerson in New York.

That may mean the timing is right for big pharma to acquire genomics companies trading at relatively cheap prices, added Scott.

“I definitely think there is an opportunity to acquire good biotech companies with good technology and balance sheets,” Scott said.

Scott and other analysts confirmed that many genomics companies are trading under value, or at a share price that gives the company a market capitalization below the amount of cash the company has on hand, but downplayed the possibility of hostile takeovers in the industry.

“It would be difficult to do a hostile takeover because you’re also buying a core group of scientists,” said Winton Gibbons, an analyst with William Blair in Chicago. The company’s real assets are in the employees, Gibbons added, who aren’t so easily converted into cash value.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.